Tirzepatide acts on both GIP and GLP‑1 receptors and is injected once weekly. This dual mechanism is one reason Mounjaro attracts attention, but suitability still depends on the person’s medical situation and tolerance.
What to know
The dose is increased in steps; do not accelerate the schedule yourself.
Nausea, diarrhoea, constipation and vomiting are among the common adverse effects.
Availability, reimbursement and dispensing rules differ between EU countries.
What a doctor assesses
A medicine is selected only after an individual medical assessment. BMI is one part of the decision, not the decision itself.
- BMI, waist circumference and weight history
- Related conditions and recent test results
- Current medicines, allergies and contraindications
- Previous treatment, goals and ability to attend follow-up
Safety and responsible access
Prescription weight-management medicines can cause adverse effects and are not suitable for everyone. The exact risks, dose escalation and monitoring differ by product. Read the current package leaflet and contact a doctor or pharmacist if anything is unclear.
Questions about this topic
Is Mounjaro automatically the ideal choice?+
No. Its mechanism and trial results do not override contraindications, tolerability, other medicines, availability or individual clinical judgement.
Can I decide from this page whether the treatment is suitable for me?+
No. This page is educational. A licensed doctor must consider your history, other medicines, contraindications and local product information.
Official sources
Sources reviewed 12 August 2026.